Participated · Series D · Jan 2026

Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva pairs a medical-device-certified mobile app with remote multidisciplinary care teams to provide evidence-based lifestyle and behavioural interventions for weight management and chronic illnesses. The platform’s embedded AI personalises treatment pathways, supports clinicians’ workflow, and maintains consistent quality at scale. Integrated into national reimbursement schemes such as Germany’s DiGA, the UK’s NHS, and Switzerland’s health system, Oviva removes long wait times and geographic barriers for patients. More than 1 million patients have already used the service, and 90+ clinical studies support its long-term efficacy. Unlike competitors such as Kry/Livi, HelloBetter, Omada Health, or Noom, Oviva focuses on reimbursed, weight-related and metabolic care in European public systems. With fresh capital, the company plans to extend its digital programmes to additional chronic indications, including hypertension and type 2 diabetes, to better manage comorbidities. The €200 million Series D provides significant resources for product expansion and deeper market penetration across Europe.

Led · Series B · Nov 2025

Delvitech is a Swiss deep-tech company that builds AI-powered 3D Automated Optical Inspection (AOI) solutions for electronics manufacturing. Its modular platform employs a self-learning neural-network architecture to classify and identify defects on difficult materials such as transparent adhesives, micro-pitch connectors, and plastic components. Beyond defect detection, the system offers predictive analytics that help manufacturers anticipate errors and improve overall quality-control efficiency. The technology is designed to reduce manual programming, speed deployment, and lower operating costs while remaining industry- and material-agnostic. Delvitech’s products serve customers in automotive, telecommunications, EMS, IoT, pharmaceuticals, defence, and industrial automation markets, with plans to expand into semiconductor inspection. Looking ahead, the company intends to scale globally, prioritising India where it expects to open a manufacturing facility in 2026 and reach a production capacity of more than 200 machines per month by 2030.

Led · Series C · Apr 2024

Bcomp develops high-performance, bio-based natural fibre composites (notably powerRibs and ampliTex) that reduce plastic content and weight while enabling easier integration into volume production. Its materials are already used at industrial scale by OEMs such as Volvo and Polestar, with ampliTex applied in the Volvo EX30 and both products used by BMW for the M4 GT4. The company highlights certifications including IATF 16949 and ISO 9001 and reports cradle-to-gate CO2 reductions up to 60%, plastic-content reductions up to 70% for interiors, and weight savings up to 50% versus traditional materials. Bcomp plans to scale production capacity to convert an advanced pipeline of commercial automotive opportunities and to expand into additional verticals including rail, buses, aviation, aerospace and consumer goods. The company also intends to support market entry in Asia and North America as part of its growth strategy. Bcomp develops and sells sustainable lightweighting solutions built on proprietary natural-fibre reinforcement technologies ampliTex™ and powerRibs™. Its natural-fibre composites aim to reduce cradle-to-gate emissions, enable dematerialisation, and offer improved vibration damping versus conventional composites. The company serves automotive, aerospace, mobility, maritime, infrastructure, and athletics customers, including BMW, Volvo Cars, and Porsche AG. Bcomp provides engineering support from idea to final part from its Fribourg headquarters. Its technologies originated from a 2011 garage project to create lightweight skis. The company plans to use new funding to scale its workforce, increase domestic and global production capacity, and strengthen its commercial footprint.

Led · Series D · Mar 2023

Lunaphore, led by CEO Ata Tuna Ciftlik, develops chip-based solutions that extract spatial proteomic and transcriptomic data from tumors and other tissues. Its platform transforms standard assays into multiplex spatial biology to support research in immunology, immuno-oncology, and neuroscience. The technology enables identification of biomarker signatures with clinical relevance to aid diagnostic development and streamline clinical trials. Lunaphore intends to use the new funding to strengthen its spatial biology portfolio and to support commercial execution to meet customer demand. The company recently completed a CHF40M first close of a Series D that includes a EUR10M venture debt facility. Lunaphore Technologies develops next-generation tissue autostainers using a microfluidics-based technology called FFeX (Fast Fluidic Exchange). The FFeX platform is designed to perform assays much faster than standard techniques and has shown promising results in tests with cancer patient samples. The company focuses on equipment for cancer research and tissue diagnostics and is working on next-generation instruments. Founded in 2014 and based in Lausanne, Switzerland, Lunaphore plans to use recent funds for market and product expansion, including a US market entry and a ramp-up of activities in Europe. Financially, the company completed a Series C2 closing that added CHF2M and contributed to a CHF25M total Series C round. The Swiss Entrepreneurs Fund invested in the Series C2 and has committed a total of CHF5M to Lunaphore. Lunaphore Technologies develops next‑generation tissue autostainers based on its FFeX (Fast Fluidic Exchange) microfluidics technology to perform assays faster than standard techniques and has demonstrated promising results with cancer patient samples. The company is based in Lausanne, Switzerland and was founded in 2014. It focuses on products for tissue analytics, pathology workflows and immuno‑oncology research. Lunaphore plans to use the Series C proceeds for market and product expansion, including a US market entry, ramping up activities in Europe and developing next‑generation instruments. The company completed a first closing of a CHF 23M Series C financing on January 15, 2020 (the round was oversubscribed). Lunaphore designs next-generation devices for cancer tissue diagnostics, including a precision medicine solution that performs ultra-rapid immunostainings. The company intends to use the new funding to obtain CE marking and support a product launch. Management says the financing validates partnerships announced in recent months and will help drive market adoption of its first products. The round was oversubscribed and finalized in August 2018. Lunaphore’s CEO, Ata Tuna Ciftlik, and board members highlighted progress toward commercialisation and market launch in the coming months. Lunaphore develops devices based on microfluidic tissue processor technology aimed at shortening the time required for cancer diagnostics assays while maintaining high precision. The company has tested its technology in collaboration with key opinion leaders and across laboratories and hospitals internationally. Lunaphore intends to use the recently raised funds for the development and market introduction of its devices. The company was founded in 2014 by Dr. Ata Tuna Ciftlik, who serves as CEO. Lunaphore is headquartered in Lausanne, Switzerland and focuses on translating its microfluidic platform into clinical diagnostic workflows. No operating metrics were disclosed in the article.

Led · Equity · Jun 2020

Spineart is a medical technology company focused on creating and advancing innovations for spine surgery. Its work centers on improving procedures and outcomes within spinal care through new surgical solutions. The company recently secured fresh capital to intensify its innovation efforts. Specifically, Spineart raised $31 million, indicating investor confidence in its strategy and market potential. The new funding strengthens its cash position and enables the firm to accelerate development and deployment of its spine-surgery offerings. Although exact operating metrics were not disclosed, the financing underscores the company’s commitment to scaling its innovation pipeline.